eFigure 1. CCRT alone versus CCRT 1 NACT or ACT with regard to rates of (A) distant metastasis-free survival, (B) overall survival, and (C) progression-free survival.
Abbreviations: ACT, adjuvant chemotherapy; CCRT, concurrent chemoradiotherapy; NACT, neoadjuvant chemotherapy. All patients were immobilized in the supine position with a head, neck, and shoulder thermoplastic mask. Two sets of images, with and without contrast, were obtained from the CT simulator for treatment planning. All patients were scanned with serial 3-mm slices from the vertex through the clavicles. Inverse intensity-modulated radiotherapy planning was performed using CORVUS version 3.0 (Best NOMOS), and a MIMiC multileaf collimator (NOMOS) was used for planning and treatment. The primary and nodal gross tumor volumes (GTV) included all gross diseases visualized by CT and/or MRI. The highrisk clinical tumor volume (CTV-1) included GTV plus a 5-to 10-mm margin and encompassed the entire nasopharyngeal mucosa plus 5-mm submucosal volume. CTV-2 was designed for potentially involved regions included in the nasopharyngeal cavity (limited only to the posterior part of the nasal cavity), maxillary sinus (limited to 5 mm anterior to the posterior nasal aperture and maxillary mucosa), pterygopalatine fossa, posterior ethmoid sinus, parapharyngeal space, skull base, anterior third of the clivus and cervical vertebra, inferior sphenoid sinus, and cavernous sinus, and it included the retropharyngeal lymph node regions from the base of the skull to the cranial edge of the second cervical vertebra. CTV of the neck nodal regions included levels II, III, IV, and V, which were outlined according to the recommendation by the RTOG/EORTC CTV delineation protocol for head and neck malignancies. The planning target volume (PTV) was created based on each volume with an additional 3-mm margin, allowing for setup variability. Critical normal structures, including the brainstem, spinal cord, parotid glands, optic nerves, chiasm, lens, eyeballs, temporal lobes, temporomandibular joints, mandible, and hypophysis, were contoured and set as organs at risk during optimization.
The dose-volume histograms of the treatment targets and critical normal structures were evaluated. The prescribed dose was 68 to 70 Gy to the PTV of GTV of nasopharynx, 60 Gy to PTV-1, 54 Gy to PTV-2, and 60 to 70 Gy to PTV of the GTV of lymph nodes in 30 to 33 fractions. For GTV and CTV, the target volumes receiving 95% of the prescribed dose were used to reflect the target coverage, and the maximal, minimal, and mean doses delivered to the target volumes were also calculated. For critical organs with functional subunits organized in series, such as the brainstem, optic chiasm, and optic nerves, the dose delivered to 5% of the volumes was examined. For critical organs with functional subunits organized in parallel, the dose delivered to 33% of the volumes was evaluated. The dose distribution was also examined slice by slice on the CT image.
